Welcome to our dedicated page for BIO-RAD LABORATORIES SEC filings (Ticker: BIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BIO-RAD LABORATORIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BIO-RAD LABORATORIES's regulatory disclosures and financial reporting.
Bio-Rad Laboratories (BIO) filed Schedule 13D/A (Amendment No. 7) updating beneficial ownership and control following family trust changes. Norman D. Schwartz reports beneficial ownership of 3,228,922 shares of Class A Common Stock, representing 14.6%. This includes 2,714,928 shares via trusts where he is sole trustee, 17,145 shares held by the Alles Institute for Medical Research with shared power, 443,434 shares held directly, and 53,415 options exercisable within sixty days of September 25, 2025.
The Alice N. Schwartz Revocable Trust holds 1,781,356 Class A shares, or 8.1%. Percentages are based on 21,992,307 Class A shares outstanding as of July 28, 2025, with Mr. Schwartz’s percentage calculated to include his 53,415 exercisable options. In Class B, Mr. Schwartz has beneficial ownership of 4,929,036 shares, or 97.2%, based on 5,070,184 Class B shares outstanding as of July 28, 2025. The filing states the purpose of the shareholders’ ownership has been control of the Company.
Bio-Rad Laboratories (BIO) reported an insider equity event by its President & COO. On 10/24/2025, 1,869 shares of Class A common stock were acquired at $0 upon the vesting of restricted stock units, followed by a disposition of 950 shares under code F at $339.75 per share. Following these transactions, 919 Class A shares are held directly.
The related RSU line shows 1,869 underlying shares delivered and 5,609 RSUs remaining outstanding. The RSUs vest over four years at 25% per year on the yearly anniversary of the grant.
Bio‑Rad Laboratories (BIO) executive Sedat Evran (EVP, Global Supply Chain) reported routine equity vesting. On 10/20/2025, 1,044 restricted stock units converted into Class A common stock at $0 per the award terms, and 335 shares were withheld at $321.90 to cover taxes. Following these transactions, Evran beneficially owned 2,232.847 Class A shares.
The RSUs relate to a grant of 4,176 units made on 10/20/2023, vesting in four equal annual installments beginning on the first anniversary of the grant date.
BlackRock, Inc. filed an amended Schedule 13G (Amendment No. 12) reporting beneficial ownership of 1,618,123 shares of Bio‑Rad Laboratories, Inc. Class A stock, representing 7.4% of the class.
BlackRock reports sole voting power over 1,561,852 shares and sole dispositive power over 1,618,123 shares, with 0 shared voting or dispositive power. The date of event triggering the filing is 09/30/2025. BlackRock certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Bio-Rad Laboratories, Inc. reported the passing of its co-founder and Director Emeritus, Alice N. Schwartz, under a Regulation FD disclosure. The company announced that she died on September 25, 2025, at the age of 99. This reflects a significant moment in the company’s history given her foundational role, but the disclosure does not describe any immediate operational or financial impacts.
The announcement was made on September 29, 2025, and a related press release was provided as an exhibit to the report. The company states that this information is being furnished, not filed, which limits how it is treated under securities law liability provisions.
Evran Sedat, Executive Vice President, Global Supply Chain at Bio-Rad Laboratories (BIO), reported insider transactions on a Form 4 covering September 5–6, 2025. The filing shows vesting and purchases that increased his direct holdings and a small sale. Specifically, 4,110 restricted stock units vested on 09/05/2025 and were converted into 4,110 shares. On 09/06/2025 an additional 864 restricted stock units vested and were converted into 864 shares. The report also lists purchases under the Employee Stock Purchase Plan earlier in 2025 totaling 83.707 shares (56.9880 and 26.7190) and a disposition of 277 shares sold at $295.43.
The transactions are reported as direct holdings and reflect routine equity compensation vesting and periodic ESPP participation, with the sale reducing holdings by 277 shares to 1,523.847 shares following the reported sale.
Roop K. Lakkaraju, EVP and Chief Financial Officer of Bio-Rad Laboratories (BIO), reported insider transactions on Form 4. The filing shows restricted stock units vesting and resulting share acquisitions and a separate disposition. On 09/05/2025, 5,480 restricted stock units vested and were acquired at $0 per unit. On 09/06/2025, 1,535 shares were acquired (noted as transaction code M) at $0 and the report records a disposition of 550 shares sold on 09/06/2025 at $295.43. The filing states the reporting person beneficially owned 2,393.659 shares following the 09/06 acquisition and 1,843.659 shares after the 550-share disposition. The filing also notes inclusion of 13.2750 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 06/30/2025. All transactions are reported as direct beneficial ownership.
Colleen Corey, EVP Global Human Resources at Bio-Rad Laboratories (BIO), reported stock award vesting and a small sale. On 09/05/2025 Ms. Corey received 2,740 restricted stock units (each convertible to one share) that vest over four years at 25% per year. On 09/06/2025 she acquired an additional 576 shares on vesting and sold 209 shares at $295.43 per share. Following these transactions she beneficially owned 19,550 shares of Bio-Rad Class A common stock (direct) for non-derivative holdings and 2,740 RSUs shown as derivative holdings.
Bio-Rad Laboratories insider change: Barry James, EVP and President, LSG, reported acquisition and disposition activity on 09/05–09/06/2025. On 09/05/2025 4,110 restricted stock units (each convertible into one Class A share) vested, and 4,110 shares are shown as beneficially owned following that vesting. On 09/06/2025 an additional 1,056 restricted stock units were recorded as acquired via vesting, increasing the reported RSU-derived holdings. The Form 4 also shows a separate transaction on 09/06/2025 with code F disposing of 378 shares at $295.43 per share. Following the transactions, the filing reports 1,587.555 and 1,209.555 shares in two non-derivative lines and 4,110 and 3,168 RSU-derived shares in derivative lines as beneficially owned in the respective entries.
Bio-Rad Laboratories director Allison Schwartz reported equity compensation activity. On September 5, 2025, she received a grant of 914 restricted stock units, each representing a contingent right to one share of Bio-Rad Class A common stock. On September 6, 92 RSUs vested and converted into 92 shares, and 33 shares were delivered at $295.43 per share to satisfy tax liabilities. Following these events, she holds 1,191 restricted stock units and 1,456 shares of Bio-Rad Class A common stock, all held directly.